An observational study in ICU Stay, Muscle Atrophy and Ultrasonography, sponsored by Taksim Egitim ve Arastirma Hastanesi. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Taksim Egitim ve Arastirma Hastanesi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, which aims to investigate the relationship between the weaning process and respiratory muscles-assessed via ultrasonographic measurement of peripheral muscle thickness-in patients over the age of 18 who have been in the intensive care unit for more than 24 hours, we will also examine whether there is a significant correlation between peripheral muscle thickness and diaphragm thickness, whether ultrasonographic findings correlate with weaning parameters, and whether peripheral muscle atrophy and diaphragm involvement are parallel or distinct processes.
Sarcopenia and muscle atrophy are commonly observed during prolonged stays in the intensive care unit (ICU). This condition is not limited to the extremities but affects all systems containing muscle tissue. Respiratory effort and the function of respiratory muscles are crucial factors during the process of weaning intubated ICU patients from mechanical ventilation. It is known that muscle loss in the ICU is a complex process associated with the severity of critical illness and mechanical ventilation, rather than resulting solely from immobilization; however, there are limited studies examining the relationship between peripheral muscle and the diaphragm in conjunction with weaning parameters. The data obtained from this study could contribute to predicting the weaning process and shaping early rehabilitation strategies in the ICU. The primary objective of this study is to evaluate the relationship between peripheral muscle thickness and diaphragm thickness-measured via ultrasonography-in patients over the age of 18 who have been in the ICU for more than 24 hours. Additionally, the study aims to investigate the impact of changes in muscle thickness on the weaning process and the ICU course, as well as to examine their associations with weaning parameters.
In the study, the following data will be recorded for patients who have stayed in the intensive care unit (ICU) for more than 24 hours: age, gender, height, weight, BMI, ICU admission diagnosis, APACHE II and SOFA scores, presence of culture-confirmed sepsis, total duration of mechanical ventilation, duration of sedation (using the Ramsay Sedation Scale), sedatives/neuromuscular blockers/corticosteroids used, nutritional method and daily protein intake, and laboratory data (albumin, CK, CRP).
Peripheral muscle measurements will be performed via ultrasonography by measuring rectus femoris or vastus intermedius thickness; the total quadriceps muscle thickness may also be recorded as data if desired.
Diaphragm measurements will be based on diaphragm thickness, diaphragm thickening fraction, and-where possible-diaphragm excursion.
Parameters to be recorded regarding weaning include: RSBI, spontaneous breathing trial outcome, MIP/NIF, tidal volume, respiratory rate, P0.1 (if available), extubation success or failure, occurrence of re-extubation within 48 hours, and the need for tracheostomy.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
This study's planned enrollment of 100 is above the median of 61 across 73 observational studies indexed under Muscular Atrophy.
Browse Muscular Atrophy studies →Taksim Egitim ve Arastirma Hastanesi is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient group aged 18 and older with an intensive care stay exceeding 24 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The measurement of peripheral muscle thickness by ultrasonography. Rectus femoris or vastus intermedius will be measured (Or the total of quadriceps).
Diaphragm thickness, diaphragm thickening fraction, and, if possible, diaphragm excursion will be measured.
Correlation Coefficient Between Total Quadriceps Muscle Thickness and End-Expiratory Diaphragm Thickness Measured by Ultrasonography
Total quadriceps muscle thickness will be calculated as the sum of rectus femoris and vastus intermedius muscle thicknesses, measured in millimeters using bedside ultrasonography. End-expiratory diaphragm thickness will be measured in millimeters using bedside ultrasonography at the same assessment. The outcome will be the Pearson or Spearman correlation coefficient between these two measurements across participants, according to the data distribution. The coefficient is dimensionless and ranges from -1 to +1. A separate coefficient will be reported for each scheduled assessment time point. Baseline assessment will include participants regardless of intubation status. Subsequent assessments will apply to participants who are intubated and those undergoing planned extubation, respectively.
Time frame: At ICU admission (baseline); 24-48 hours after intubation; and immediately before planned extubation.
Correlation Coefficient Between Total Quadriceps Muscle Thickness and Diaphragm Thickening Fraction Measured by Ultrasonography
Total quadriceps muscle thickness will be calculated as the sum of rectus femoris and vastus intermedius muscle thicknesses, measured in millimeters using bedside ultrasonography. Diaphragm thickening fraction will be calculated from ultrasound measurements as: \[(end-inspiratory diaphragm thickness - end-expiratory diaphragm thickness) / end-expiratory diaphragm thickness\] × 100, and expressed as a percentage. The outcome will be the Pearson or Spearman correlation coefficient between total quadriceps muscle thickness and diaphragm thickening fraction across participants, according to the data distribution. The coefficient is dimensionless and ranges from -1 to +1. A separate coefficient will be reported for each scheduled assessment time point. Baseline assessment will include participants regardless of intubation status. Subsequent assessments will apply to participants who are intubated and those undergoing planned extubation, respectively.
Time frame: At ICU admission (baseline); 24-48 hours after intubation; and immediately before planned extubation.
Mean Percentage Change From Baseline in Total Quadriceps Muscle Thickness Measured by Ultrasonography
Total quadriceps muscle thickness will be calculated as the sum of rectus femoris and vastus intermedius muscle thicknesses, measured in millimeters using bedside ultrasonography. For each participant, percentage change from the ICU admission measurement will be calculated as: \[(follow-up thickness - baseline thickness) / baseline thickness\] × 100. Negative values indicate a reduction in muscle thickness. The mean of the participant-level percentage changes will be reported separately for each follow-up time point using participants with paired baseline and follow-up measurements. The outcome unit is percent (%).
Time frame: From ICU admission (baseline) to 24-48 hours after intubation; and from ICU admission (baseline) to immediately before planned extubation.
Mean Percentage Change From Baseline in End-Expiratory Diaphragm Thickness Measured by Ultrasonography
End-expiratory diaphragm thickness will be measured in millimeters using bedside ultrasonography. For each participant, percentage change from the ICU admission measurement will be calculated as: \[(follow-up thickness - baseline thickness) / baseline thickness\] × 100. Negative values indicate a reduction in diaphragm thickness. The mean of the participant-level percentage changes will be reported separately for each follow-up time point using participants with paired baseline and follow-up measurements. The outcome unit is percent (%).
Time frame: From ICU admission (baseline) to 24-48 hours after intubation; and from ICU admission (baseline) to immediately before planned extubation.
Percentage of Participants With Successful Extubation at 48 Hours
Successful extubation will be defined as remaining alive and free from invasive mechanical ventilation throughout the first 48 hours following the first planned extubation during the ICU stay. Extubation outcome will be determined from clinical follow-up and medical records. The percentage will be calculated as the number of participants meeting the success definition divided by the number of participants undergoing the first planned extubation, multiplied by 100. Noninvasive respiratory support alone will not constitute failure under this definition.
Time frame: From the first planned extubation through 48 hours after extubation.
Percentage of Participants Requiring Reintubation Within 48 Hours After Planned Extubation
Reintubation will be defined as reinsertion of an endotracheal tube within 48 hours after the first planned extubation during the ICU stay, as documented in medical records. The percentage will be calculated as the number of participants requiring reintubation within 48 hours divided by the number of participants undergoing the first planned extubation, multiplied by 100.
Time frame: From the first planned extubation through 48 hours after extubation.
No study locations are listed for this record.
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.
Of 36 non-industry observational studies under Muscular Atrophy, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 66. This study's planned 11 months is below that.
Counting every sponsor, half of 38 studies reached it within 35 months; a quarter within 18 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taksim Egitim ve Arastirma Hastanesi